Glenmede Trust CO Na Tg Therapeutics, Inc. Transaction History

Glenmede Trust CO Na

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$5.01 - $11.83 $77,965 - $184,098	15,562 New	15,562 $184,000
Q3 2021 Nov 15, 2021	SELL	$21.78 - $40.45 $211,723 - $393,214	-9,721 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$32.5 - $48.96 $13,552 - $20,416	-417 Reduced 4.11%	9,721 $377,000
Q1 2021 May 18, 2021	BUY	$41.61 - $54.3 $7,406 - $9,665	178 Added 1.79%	10,138 $488,000
Q4 2020 Feb 16, 2021	BUY	$25.27 - $54.9 $251,689 - $546,804	9,960 New	9,960 $518,000

338

88.3M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.